Global Single Nucleotide Polymorphism

Single Nucleotide Polymorphism Comprehensive Study by Type (Synonymous SNPs, Non-Synonymous SNPs), Application (Association Studies, Linkage Disequilibrium, Haplotype Mapping), Technology (SNP Genechips and Microarrays, Taqman Assay, SNP Genotyping Based Upon Pyrosequencing, Sn Plex Based Upon Applied Biosystems, Sequenom Masarray Maldi-TOF, RFLP, SSCP, Arms, Others) Players and Region - Global Market Outlook to 2027

Single Nucleotide Polymorphism Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Single Nucleotide Polymorphism is a variant in the DNA sequence that occurs when a single nucleotide in the sequence is different from the norm, at least one percent of the population. SNPs occur inside a gene that creates different variants of the gene. In common SNPs have no effect on health or development. Many studies define SNPs help to predict an individual’s response to drugs and other sensitivity to environmental factors including toxins, and developing of any diseases. SNPs also helps to track the inheritance of disease genes within families. Many studies are going on identifying the association of SNPs with complex diseases including diabetes, cancer, and other heart disease.This growth is primarily driven by Growing Applications of SNPs in Several Life Sciences & Biotechnology Aspects and Increasing Generality of Diabetes, Cardiovascular Diseases, and Cancer.

Globally, a noticeable market trend is evident Advancement in SNP Technology . Major Players, such as Affymetrix Inc. (United States), Beckman Coulter (United States), Bio-Rad Laboratories (United States), GE Healthcare (United States), Sequenom Inc. (United States), Roche Holding AG (Switzerland), Qiagen (Germany), Fluidigm Corporation (United States), Agilent Technologies (United States) and Thermo Fisher Scientific Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In Jan 2019, NRGene and Macrogen Corp announced the launch of joint sequencing-based genotyping service. This new service also provides ultra-high density nucleotide polymorphism at a low cost per data point.

Market Drivers
  • Growing Applications of SNPs in Several Life Sciences & Biotechnology Aspects
  • Increasing Generality of Diabetes, Cardiovascular Diseases, and Cancer

Market Trend
  • Advancement in SNP Technology
  • Automation in Genotyping of Single Nucleotide Polymorphisms

Restraints
  • Inadequate Reimbursement Policies Restrict the Growth of SNPs Genotyping Market

Opportunities
Agricultural Biotechnology, Diagnostic Research, Pharmaceuticals, Pharmacogenomics, and Animal & Livestock Breeding

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Single Nucleotide Polymorphism Study Sheds Light on
— The Single Nucleotide Polymorphism Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Single Nucleotide Polymorphism industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Single Nucleotide Polymorphism industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Synonymous SNPs
  • Non-Synonymous SNPs
By Application
  • Association Studies
  • Linkage Disequilibrium
  • Haplotype Mapping
By Technology
  • SNP Genechips and Microarrays
  • Taqman Assay
  • SNP Genotyping Based Upon Pyrosequencing
  • Sn Plex Based Upon Applied Biosystems
  • Sequenom Masarray Maldi-TOF
  • RFLP
  • SSCP
  • Arms
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Applications of SNPs in Several Life Sciences & Biotechnology Aspects
      • 3.2.2. Increasing Generality of Diabetes, Cardiovascular Diseases, and Cancer
    • 3.3. Market Trends
      • 3.3.1. Advancement in SNP Technology
      • 3.3.2. Automation in Genotyping of Single Nucleotide Polymorphisms
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Single Nucleotide Polymorphism, by Type, Application, Technology and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Single Nucleotide Polymorphism (Value)
      • 5.2.1. Global Single Nucleotide Polymorphism by: Type (Value)
        • 5.2.1.1. Synonymous SNPs
        • 5.2.1.2. Non-Synonymous SNPs
      • 5.2.2. Global Single Nucleotide Polymorphism by: Application (Value)
        • 5.2.2.1. Association Studies
        • 5.2.2.2. Linkage Disequilibrium
        • 5.2.2.3. Haplotype Mapping
      • 5.2.3. Global Single Nucleotide Polymorphism by: Technology (Value)
        • 5.2.3.1. SNP Genechips and Microarrays
        • 5.2.3.2. Taqman Assay
        • 5.2.3.3. SNP Genotyping Based Upon Pyrosequencing
        • 5.2.3.4. Sn Plex Based Upon Applied Biosystems
        • 5.2.3.5. Sequenom Masarray Maldi-TOF
        • 5.2.3.6. RFLP
        • 5.2.3.7. SSCP
        • 5.2.3.8. Arms
        • 5.2.3.9. Others
      • 5.2.4. Global Single Nucleotide Polymorphism Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Single Nucleotide Polymorphism (Price)
      • 5.3.1. Global Single Nucleotide Polymorphism by: Type (Price)
  • 6. Single Nucleotide Polymorphism: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Affymetrix Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Beckman Coulter (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bio-Rad Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sequenom Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Qiagen (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fluidigm Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Agilent Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Thermo Fisher Scientific Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Single Nucleotide Polymorphism Sale, by Type, Application, Technology and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Single Nucleotide Polymorphism (Value)
      • 7.2.1. Global Single Nucleotide Polymorphism by: Type (Value)
        • 7.2.1.1. Synonymous SNPs
        • 7.2.1.2. Non-Synonymous SNPs
      • 7.2.2. Global Single Nucleotide Polymorphism by: Application (Value)
        • 7.2.2.1. Association Studies
        • 7.2.2.2. Linkage Disequilibrium
        • 7.2.2.3. Haplotype Mapping
      • 7.2.3. Global Single Nucleotide Polymorphism by: Technology (Value)
        • 7.2.3.1. SNP Genechips and Microarrays
        • 7.2.3.2. Taqman Assay
        • 7.2.3.3. SNP Genotyping Based Upon Pyrosequencing
        • 7.2.3.4. Sn Plex Based Upon Applied Biosystems
        • 7.2.3.5. Sequenom Masarray Maldi-TOF
        • 7.2.3.6. RFLP
        • 7.2.3.7. SSCP
        • 7.2.3.8. Arms
        • 7.2.3.9. Others
      • 7.2.4. Global Single Nucleotide Polymorphism Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Single Nucleotide Polymorphism (Price)
      • 7.3.1. Global Single Nucleotide Polymorphism by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Single Nucleotide Polymorphism: by Type(USD Million)
  • Table 2. Single Nucleotide Polymorphism Synonymous SNPs , by Region USD Million (2016-2021)
  • Table 3. Single Nucleotide Polymorphism Non-Synonymous SNPs , by Region USD Million (2016-2021)
  • Table 4. Single Nucleotide Polymorphism: by Application(USD Million)
  • Table 5. Single Nucleotide Polymorphism Association Studies , by Region USD Million (2016-2021)
  • Table 6. Single Nucleotide Polymorphism Linkage Disequilibrium , by Region USD Million (2016-2021)
  • Table 7. Single Nucleotide Polymorphism Haplotype Mapping , by Region USD Million (2016-2021)
  • Table 8. Single Nucleotide Polymorphism: by Technology(USD Million)
  • Table 9. Single Nucleotide Polymorphism SNP Genechips and Microarrays , by Region USD Million (2016-2021)
  • Table 10. Single Nucleotide Polymorphism Taqman Assay , by Region USD Million (2016-2021)
  • Table 11. Single Nucleotide Polymorphism SNP Genotyping Based Upon Pyrosequencing , by Region USD Million (2016-2021)
  • Table 12. Single Nucleotide Polymorphism Sn Plex Based Upon Applied Biosystems , by Region USD Million (2016-2021)
  • Table 13. Single Nucleotide Polymorphism Sequenom Masarray Maldi-TOF , by Region USD Million (2016-2021)
  • Table 14. Single Nucleotide Polymorphism RFLP , by Region USD Million (2016-2021)
  • Table 15. Single Nucleotide Polymorphism SSCP , by Region USD Million (2016-2021)
  • Table 16. Single Nucleotide Polymorphism Arms , by Region USD Million (2016-2021)
  • Table 17. Single Nucleotide Polymorphism Others , by Region USD Million (2016-2021)
  • Table 18. South America Single Nucleotide Polymorphism, by Country USD Million (2016-2021)
  • Table 19. South America Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 20. South America Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 21. South America Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 22. Brazil Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 23. Brazil Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 24. Brazil Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 25. Argentina Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 26. Argentina Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 27. Argentina Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 28. Rest of South America Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 29. Rest of South America Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 30. Rest of South America Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 31. Asia Pacific Single Nucleotide Polymorphism, by Country USD Million (2016-2021)
  • Table 32. Asia Pacific Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 33. Asia Pacific Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 34. Asia Pacific Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 35. China Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 36. China Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 37. China Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 38. Japan Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 39. Japan Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 40. Japan Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 41. India Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 42. India Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 43. India Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 44. South Korea Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 45. South Korea Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 46. South Korea Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 47. Taiwan Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 48. Taiwan Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 49. Taiwan Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 50. Australia Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 51. Australia Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 52. Australia Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 55. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 56. Europe Single Nucleotide Polymorphism, by Country USD Million (2016-2021)
  • Table 57. Europe Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 58. Europe Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 59. Europe Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 60. Germany Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 61. Germany Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 62. Germany Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 63. France Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 64. France Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 65. France Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 66. Italy Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 67. Italy Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 68. Italy Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 69. United Kingdom Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 70. United Kingdom Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 71. United Kingdom Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 72. Netherlands Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 73. Netherlands Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 74. Netherlands Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 75. Rest of Europe Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 76. Rest of Europe Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 77. Rest of Europe Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 78. MEA Single Nucleotide Polymorphism, by Country USD Million (2016-2021)
  • Table 79. MEA Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 80. MEA Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 81. MEA Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 82. Middle East Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 83. Middle East Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 84. Middle East Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 85. Africa Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 86. Africa Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 87. Africa Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 88. North America Single Nucleotide Polymorphism, by Country USD Million (2016-2021)
  • Table 89. North America Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 90. North America Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 91. North America Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 92. United States Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 93. United States Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 94. United States Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 95. Canada Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 96. Canada Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 97. Canada Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 98. Mexico Single Nucleotide Polymorphism, by Type USD Million (2016-2021)
  • Table 99. Mexico Single Nucleotide Polymorphism, by Application USD Million (2016-2021)
  • Table 100. Mexico Single Nucleotide Polymorphism, by Technology USD Million (2016-2021)
  • Table 101. Single Nucleotide Polymorphism: by Type(USD/Units)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Single Nucleotide Polymorphism: by Type(USD Million)
  • Table 113. Single Nucleotide Polymorphism Synonymous SNPs , by Region USD Million (2022-2027)
  • Table 114. Single Nucleotide Polymorphism Non-Synonymous SNPs , by Region USD Million (2022-2027)
  • Table 115. Single Nucleotide Polymorphism: by Application(USD Million)
  • Table 116. Single Nucleotide Polymorphism Association Studies , by Region USD Million (2022-2027)
  • Table 117. Single Nucleotide Polymorphism Linkage Disequilibrium , by Region USD Million (2022-2027)
  • Table 118. Single Nucleotide Polymorphism Haplotype Mapping , by Region USD Million (2022-2027)
  • Table 119. Single Nucleotide Polymorphism: by Technology(USD Million)
  • Table 120. Single Nucleotide Polymorphism SNP Genechips and Microarrays , by Region USD Million (2022-2027)
  • Table 121. Single Nucleotide Polymorphism Taqman Assay , by Region USD Million (2022-2027)
  • Table 122. Single Nucleotide Polymorphism SNP Genotyping Based Upon Pyrosequencing , by Region USD Million (2022-2027)
  • Table 123. Single Nucleotide Polymorphism Sn Plex Based Upon Applied Biosystems , by Region USD Million (2022-2027)
  • Table 124. Single Nucleotide Polymorphism Sequenom Masarray Maldi-TOF , by Region USD Million (2022-2027)
  • Table 125. Single Nucleotide Polymorphism RFLP , by Region USD Million (2022-2027)
  • Table 126. Single Nucleotide Polymorphism SSCP , by Region USD Million (2022-2027)
  • Table 127. Single Nucleotide Polymorphism Arms , by Region USD Million (2022-2027)
  • Table 128. Single Nucleotide Polymorphism Others , by Region USD Million (2022-2027)
  • Table 129. South America Single Nucleotide Polymorphism, by Country USD Million (2022-2027)
  • Table 130. South America Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 131. South America Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 132. South America Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 133. Brazil Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 134. Brazil Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 135. Brazil Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 136. Argentina Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 137. Argentina Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 138. Argentina Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 139. Rest of South America Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 140. Rest of South America Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 141. Rest of South America Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 142. Asia Pacific Single Nucleotide Polymorphism, by Country USD Million (2022-2027)
  • Table 143. Asia Pacific Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 144. Asia Pacific Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 145. Asia Pacific Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 146. China Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 147. China Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 148. China Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 149. Japan Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 150. Japan Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 151. Japan Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 152. India Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 153. India Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 154. India Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 155. South Korea Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 156. South Korea Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 157. South Korea Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 158. Taiwan Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 159. Taiwan Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 160. Taiwan Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 161. Australia Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 162. Australia Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 163. Australia Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 164. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 165. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 166. Rest of Asia-Pacific Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 167. Europe Single Nucleotide Polymorphism, by Country USD Million (2022-2027)
  • Table 168. Europe Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 169. Europe Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 170. Europe Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 171. Germany Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 172. Germany Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 173. Germany Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 174. France Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 175. France Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 176. France Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 177. Italy Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 178. Italy Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 179. Italy Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 180. United Kingdom Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 181. United Kingdom Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 182. United Kingdom Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 183. Netherlands Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 184. Netherlands Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 185. Netherlands Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 186. Rest of Europe Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 187. Rest of Europe Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 188. Rest of Europe Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 189. MEA Single Nucleotide Polymorphism, by Country USD Million (2022-2027)
  • Table 190. MEA Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 191. MEA Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 192. MEA Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 193. Middle East Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 194. Middle East Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 195. Middle East Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 196. Africa Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 197. Africa Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 198. Africa Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 199. North America Single Nucleotide Polymorphism, by Country USD Million (2022-2027)
  • Table 200. North America Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 201. North America Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 202. North America Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 203. United States Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 204. United States Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 205. United States Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 206. Canada Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 207. Canada Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 208. Canada Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 209. Mexico Single Nucleotide Polymorphism, by Type USD Million (2022-2027)
  • Table 210. Mexico Single Nucleotide Polymorphism, by Application USD Million (2022-2027)
  • Table 211. Mexico Single Nucleotide Polymorphism, by Technology USD Million (2022-2027)
  • Table 212. Single Nucleotide Polymorphism: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Single Nucleotide Polymorphism: by Type USD Million (2016-2021)
  • Figure 5. Global Single Nucleotide Polymorphism: by Application USD Million (2016-2021)
  • Figure 6. Global Single Nucleotide Polymorphism: by Technology USD Million (2016-2021)
  • Figure 7. South America Single Nucleotide Polymorphism Share (%), by Country
  • Figure 8. Asia Pacific Single Nucleotide Polymorphism Share (%), by Country
  • Figure 9. Europe Single Nucleotide Polymorphism Share (%), by Country
  • Figure 10. MEA Single Nucleotide Polymorphism Share (%), by Country
  • Figure 11. North America Single Nucleotide Polymorphism Share (%), by Country
  • Figure 12. Global Single Nucleotide Polymorphism: by Type USD/Units (2016-2021)
  • Figure 13. Global Single Nucleotide Polymorphism share by Players 2021 (%)
  • Figure 14. Global Single Nucleotide Polymorphism share by Players (Top 3) 2021(%)
  • Figure 15. Global Single Nucleotide Polymorphism share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Affymetrix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Affymetrix Inc. (United States) Revenue: by Geography 2021
  • Figure 19. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 20. Beckman Coulter (United States) Revenue: by Geography 2021
  • Figure 21. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 23. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 24. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 25. Sequenom Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sequenom Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Qiagen (Germany) Revenue: by Geography 2021
  • Figure 31. Fluidigm Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Fluidigm Corporation (United States) Revenue: by Geography 2021
  • Figure 33. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 34. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 35. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Global Single Nucleotide Polymorphism: by Type USD Million (2022-2027)
  • Figure 38. Global Single Nucleotide Polymorphism: by Application USD Million (2022-2027)
  • Figure 39. Global Single Nucleotide Polymorphism: by Technology USD Million (2022-2027)
  • Figure 40. South America Single Nucleotide Polymorphism Share (%), by Country
  • Figure 41. Asia Pacific Single Nucleotide Polymorphism Share (%), by Country
  • Figure 42. Europe Single Nucleotide Polymorphism Share (%), by Country
  • Figure 43. MEA Single Nucleotide Polymorphism Share (%), by Country
  • Figure 44. North America Single Nucleotide Polymorphism Share (%), by Country
  • Figure 45. Global Single Nucleotide Polymorphism: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Affymetrix Inc. (United States)
  • Beckman Coulter (United States)
  • Bio-Rad Laboratories (United States)
  • GE Healthcare (United States)
  • Sequenom Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Qiagen (Germany)
  • Fluidigm Corporation (United States)
  • Agilent Technologies (United States)
  • Thermo Fisher Scientific Inc. (United States)
Additional players considered in the study are as follows:
Nptel (India) , Shanghai Biochip Co. Ltd. (China) , GenScript (China)
Select User Access Type

Key Highlights of Report


Mar 2022 233 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Single Nucleotide Polymorphism Quantitative research analysis
Global Single Nucleotide Polymorphism Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Single Nucleotide Polymorphism Market are Affymetrix Inc. (United States), Beckman Coulter (United States), Bio-Rad Laboratories (United States), GE Healthcare (United States), Sequenom Inc. (United States), Roche Holding AG (Switzerland), Qiagen (Germany), Fluidigm Corporation (United States), Agilent Technologies (United States) and Thermo Fisher Scientific Inc. (United States) etc.
Single Nucleotide Polymorphism is a variant in the DNA sequence that occurs when a single nucleotide in the sequence is different from the norm, at least one percent of the population. SNPs occur inside a gene that creates different variants of the gene. In common SNPs have no effect on health or development. Many studies define SNPs help to predict an individual’s response to drugs and other sensitivity to environmental factors including toxins, and developing of any diseases. SNPs also helps to track the inheritance of disease genes within families. Many studies are going on identifying the association of SNPs with complex diseases including diabetes, cancer, and other heart disease.

Know More About Global Single Nucleotide Polymorphism Report?

Have a Query? Click Here

Other Related Reports

Ambulatory Surgery Center Comprehensive Study by Type (Single-specialty Centers, Multi-specialty Centers), Application (Ophthalmology, Pain Management, Gastroenterology, Orthopedics, Others), Service...
$ 3750
Corneal Transplant Comprehensive Study by Type (Penetrating Keratoplasty, Endothelial Keratoplasty, Descemet Stripping Automated Endothelial Keratoplasty, Corneal Limbal Stem Cell Transplant, Others)...
$ 3750
Hospitals and Outpatient Care Centers Comprehensive Study by Type (Hospitals (Emergency department, Cardiology, Intensive care unit, others), Outpatient Care Centres (Ambulatory Surgical & Emergency ...
$ 3750
Foot & Ankle Braces Comprehensive Study by Type (Lace-Up Ankle Braces, Rigid Ankle Braces, Soft Ankle Braces, Others), Application (Clinics, Hospitals, Others), Category (Ankle Splints & Stirrups, El...
$ 3750
Integrated Operating Room Comprehensive Study by Type (High-Definition (HD) Display System, Audio and Video Management System, Recording and Documentation System), Application (General Surgery, Ortho...
$ 3500
Non-Invasive Prenatal Testing Comprehensive Study by Type (High & Average Risk, Low Risk), Application (0-12 weeks, 13-24 weeks, 25-36 weeks), Consumables (Assay Kits & Reagents, Disposables), Instru...
$ 3750